- Home
- FRAF vs EDIT Comparison
FRAF vs EDIT Comparison
Compare FRAF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRAF
- EDIT
- Stock Information
- Founded
- FRAF 1906
- EDIT 2013
- Country
- FRAF United States
- EDIT United States
- Employees
- FRAF N/A
- EDIT N/A
- Industry
- FRAF Major Banks
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRAF Finance
- EDIT Health Care
- Exchange
- FRAF Nasdaq
- EDIT Nasdaq
- Market Cap
- FRAF 152.9M
- EDIT 179.1M
- IPO Year
- FRAF N/A
- EDIT 2016
- Fundamental
- Price
- FRAF $36.76
- EDIT $2.56
- Analyst Decision
- FRAF
- EDIT Buy
- Analyst Count
- FRAF 0
- EDIT 12
- Target Price
- FRAF N/A
- EDIT $6.20
- AVG Volume (30 Days)
- FRAF 48.9K
- EDIT 3.0M
- Earning Date
- FRAF 07-22-2025
- EDIT 08-06-2025
- Dividend Yield
- FRAF 3.60%
- EDIT N/A
- EPS Growth
- FRAF N/A
- EDIT N/A
- EPS
- FRAF 2.62
- EDIT N/A
- Revenue
- FRAF $71,310,000.00
- EDIT $35,837,000.00
- Revenue This Year
- FRAF N/A
- EDIT N/A
- Revenue Next Year
- FRAF N/A
- EDIT N/A
- P/E Ratio
- FRAF $13.97
- EDIT N/A
- Revenue Growth
- FRAF 5.61
- EDIT N/A
- 52 Week Low
- FRAF $27.00
- EDIT $0.91
- 52 Week High
- FRAF $40.76
- EDIT $6.05
- Technical
- Relative Strength Index (RSI)
- FRAF 58.64
- EDIT 66.88
- Support Level
- FRAF $33.87
- EDIT $2.11
- Resistance Level
- FRAF $35.42
- EDIT $2.37
- Average True Range (ATR)
- FRAF 0.96
- EDIT 0.26
- MACD
- FRAF 0.26
- EDIT 0.01
- Stochastic Oscillator
- FRAF 94.72
- EDIT 66.49
About FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.